Adjuvant modulation of immune responses to tuberculosis subunit vaccines

Infection and Immunity

Volumn 65, Issue 2, 1997, Pages 623-629

  Lindblad, Erik B ^a   Elhay, Martin J ^a   Silva, Regina ^b   Appelberg, Rui ^b   Andersen, Peter ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; BCG VACCINE; CYTOKINE; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; FREUND ADJUVANT; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; MESSENGER RNA; POLYINOSINIC POLYCYTIDYLIC ACID; QUIL A; RIBI ADJUVANT; SAPONIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; HELPER CELL; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUBERCULOSIS;

EID: 0031020339     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.65.2.623-629.1997     Document Type: Article

References (45)

1. Andersen, P., D. Askgaard, L. Ljungqvist, M. W. Bentzon, and I. Heron. 1991. T-cell proliferative response to antigens secreted from Mycobacterium tuberculosis. Infect. Immun. 59:1558-1563.
2. Andersen, P., D. Askgaard, L. Ljungqvist, J. Bennedsen, and I. Heron. 1991. Proteins released from Mycobacterium tuberculosis during growth. Infect. Immun. 59:1905-1910.
3. Andersen, P., and I. Heron. 1993. Specificity of a protective memory immune response against Mycobacterium tuberculosis. Infect. Immun. 61:844-851.
4. Andersen, P. 1994. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect. Immun. 62:2536-2544.
5. Audibert, F. M., and L. D. Lise. 1993. Adjuvants: current status, clinical perspectives and future prospects. Immunol. Today 14:281-284.
6. Bancroft, G. J., R. D. Schreiber, and E. R. Unanue. 1991. Natural immunity: a T-cell-independent pathway of macrophage activation, defined in the scid mouse. Immunol. Rev. 124:5-24.
7. Barry, D. W., E. Staton, and R. E. Mayner. 1974. Inactivated influenza vaccine efficacy: diminished antigenicity of split-product vaccines in mice. Infect. Immun. 10:1329-1336.
8. Bloom, B. R., and P. E. M. Fine. 1994. The BCG experience: implications for future vaccines against tuberculosis, p. 531-557. In B. R. Bloom (ed.), Tuberculosis: pathogenesis, protection, and control. ASM Press, Washington, D.C.
9. Bomford, R. 1980. The comparative selectivity of adjuvants for humoral and cell-mediated immunity. II. Clin. Exp. Immunol. 39:435-441.
10. Castro, A. C., P. Minóprio, and R. Appelberg. 1995. The relative impact of bacterial virulence and host genetic background on cytokine expression during Mycobacterium avium infection of mice. Immunology 85:556-561.
11. Chatelain, R., K. Varkila, and R. L. Coffman. 1992. IL-4 induces a Th2 response in Leishmania major-infected mice. J. Immunol. 148:1182-1187.
12. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by guanidine isothiocyanate-chloroform extraction. Anal. Biochem. 162:156-159.
13. Cooper, A. M., D. K. Dalton, T. A. Stewart, J. P. Griffin, D. G. Russell, and I. M. Orme. 1993. Disseminated tuberculosis in interferon-7 gene-disrupted mice. J. Exp. Med. 178:2243-2247.
14. D'Andrea, A., M. Aste-Amezaga, N. M. Valiante, X. Ma, M. Kubin, and G. Trichieri. 1993. Interleukin-10 inhibits human lymphocyte IFN-γ production by suppressing natural killer cell stimulatory factor/interleukin-12 synthesis in accessory cells. J. Exp. Med. 178:1041-1048.
15. Flynn, J. A., J. Chan, K. J. Triebold, D. K. Dalton, T. A. Stewart, and B. R. Bloom. 1993. An essential role for interferon-γ in resistance to M. tuberculosis infection. J. Exp. Med. 178:2249-2254.
16. Grün, J. L., and P. H. Maurer. 1989. Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. Cell. Immunol. 121:134-145.
17. Gupta, R. K., E. H. Relyveld, E. B. Lindblad, B. Bizzini, S. Ben-Efraim, and C. K. Gupta. 1993. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 11:293-306.
18. Haanen, J. B. A. G., R. de Waal Malefijt, P. C. M. Res, E. M. Kraakman, T. H. M. Ottenhoff, R. R. P. de Vries, and H. Spits. 1991. Selection of human T-helper type 1-like T-cell subset by Mycobacteria. J. Exp. Med. 174:583-592.
19. Jolles, P., and A. Paraf. 1973. Chemical and biological basis of adjuvants. Mol. Biol. Biochem. Biophys. 13:11-52.
20. Kraaijeveld, C. A., H. Snippe, M. Harmsen, and B. J. Bautahar-Trouw. 1980. Dimethyldioctadecylammonium bromide as an adjuvant for delayed type hypersensitivity and cell-mediated immunity against Semliki Forest virus in mice. Arch. Virol. 65:211-217.
21. Lindblad, E. B. 1995. Aluminum adjuvants, p. 21-35. In D. E. S. Stewart-Tull (ed.), The theory and practical application of adjuvants. John Wiley & Sons, New York, N.Y.
22. Loppnow, H., L. Brade, H. Brade, E. T. Rietschel, S. Kusumoto, T. Shiba, and H.-D. Flad. 1986. Induction of human interleukin 1 by bacterial and synthetic lipid A. Eur. J. Immunol. 16:1263-1267.
23. Lövgren, K. 1987. Construction and potential of the ISCOM as immunogen. Ph.D. thesis. National Veterinary Institute, Uppsala, Sweden.
24. Manetti, R., F. Annunziato, L. Tomasevic, V. Gianno, P. Parronchi, S. Romagnani, and E. Maggi. 1995. Polyinosinic acid:polycytidylic acid promotes T helper type 1-specific immune responses by stimulating macrophage production of interferon-β and interleukin-12. Eur. J. Immunol. 25:2656-2660.
25. Mosmann, T. R., and R. L. Coffman. 1989. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145-173.
26. Orme, I. M., P. Andersen, and W. H. Boom. 1993. T cell response to Mycobacterium tuberculosis. J. Infect. Dis. 167:1481-1497.
27. Pal, P. G., and M. A. Horwitz. 1992. Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Infect. Immun. 60:4781-4792.
28. Powrie, F., S. Menon, and R. L. Coffman. 1993. Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo. Eur. J. Immunol. 23:2223-2229.
29. Relkin, F., C. P. Aranda, S. M. Garay, R. Smith, K. A. Berkowitz, and W. N. Rom. 1994. Pleural tuberculosis and HIV infection. Chest 105:1338-1341.
30. Roberts, A. D., M. G. Sonnenberg, D. J. Ordway, S. K. Furney, P. J. Brennan, J. T. Belisle, and I. M. Orme. 1995. Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis. Immunology 85:502-508.
31. Salgame, P., J. S. Abrams, C. Clayberger, H. Goldstein, J. Convit, R. L. Modlin, and B. R. Bloom. 1991. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 254:279-282.
32. Scharton-Kersten, T., and P. Scott. 1995. The role of the innate immune response in Th1 cell development following Leishmania major infection. J. Leukocyte Biol. 57:515-522.
33. Scott, P. 1988. The role of Th1 and Th2 cells in experimental cutaneous leishmaniasis. Exp. Parasitol. 68:369-372.
34. Selwyn, P. A., D. Hartel, V. A. Lewis, E. E. Schoenbaum, S. H. Vermund, R. S. Klein, A. T. Walker, and G. H. Friedland. 1989. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N. Engl. J. Med. 320:545-550.
35. Selwyn, P. A., B. M. Sckell, P. Alcabes, G. H. Friedland, R. S. Klein, and E. E. Schoenbaum. 1992. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA 268:504-509.
36. Shafer, R. W., K. D. Chirgwin, A. E. Glatt, M. A. Dadhouh, S. H. Landesman, and B. Suster. 1991. HIV prevalence, immunosuppression and drug resistance in patients with tuberculosis in an area endemic for AIDS. AIDS 5:399-405.
37. Smith, D. W. 1985. Protective effect of BCG in experimental tuberculosis. S. Karger, Basel, Switzerland.
38. Stanfield, J. P., D. Gall, and P. M. Bracken. 1973. Single-dose antenatal tetanus immunisation. Lancet ii:215-219.
39. Sørensen, A. L., S. Nagai, G. Houen, P. Andersen, and Å. B. Andersen. 1995. Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect. Immun. 63:1710-1717.
40. Trinchieri, G. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13:251-276.
41. Veronesi, R., A. Correa, and D. Alterio. 1970. Single dose immunization against tetanus. Promising results in human trials. Rev. Inst. Med. Trop. 12:46-54.
42. Wallis, R. S., M. Amir-Tahmasseb, and J. J. Ellner. 1990. Induction of interleukin 1 and tumor necrosis factor by mycobacterial proteins: the monocyte Western blot. Proc. Natl. Acad. Sci. USA 87:3348-3352.
43. Wolf, S. F., J. Bliss, K. Stokes, and J. Sypek. 1995. Activity of IL-12 as adjuvant in promoting Th1 and Th2 recall responses. Res. Immunol. 146: 486-493.
44. Yamamura, M., K. Uyemura, R. J. Deans, K. Weinberg, T. H. Rea, B. R. Bloom, and R. L. Modlin. 1991. Defining prospective responses to pathogens: cytokine profiles in leprosy lesions. Science 254:277-279.
45. pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J. Exp. Med. 179:1285-1295.